---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-25-000003"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:23:49.927650+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M

## Summary
- Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.
- Initial FY2025 revenue guidance of $940-955M, representing 17-19% growth over FY2024.
- Soft launch of Inspire V neurostimulator with over 40 implants completed in Singapore and U.S.
- Appointed Jason Kelly as Chief Manufacturing and Quality Officer effective Jan 20, 2025; Dr. Sparks, CMO, left.
- Activated 72 new U.S. centers in Q4 (total 1,435); 12 new sales territories (total 335).

## SEC filing metadata
- accession: 0001609550-25-000003
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000003/0001609550-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000003/insp-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-25-000003
- JSON: https://secwatch.observer/filing/0001609550-25-000003.json
- Plain text: https://secwatch.observer/filing/0001609550-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.